CRYOPORT, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
CRYOPORT, INC. (CYRX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $521.06 thousand for the 12-month period ending 2016-03-31, per its 10-KT filed 2017-03-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2017-03-13
- CRYOPORT, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2016 was $521.06K, a 36.99% decline from fiscal 2015.
- CRYOPORT, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2015 was $826.92K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2016-03-31 | $521.06K 10-KT · filed 2017-03-13 |
| 2015-03-31 | $826.92K 10-K · filed 2016-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |